Canaccord Genuity Maintains Buy on Seres Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst John Newman reaffirms a Buy rating for Seres Therapeutics (NASDAQ:MCRB) and maintains a $10 price target.
September 13, 2024 | 6:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst John Newman reaffirms a Buy rating for Seres Therapeutics and maintains a $10 price target, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a maintained price target of $10 by Canaccord Genuity suggests a positive outlook for Seres Therapeutics. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100